Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.41 |
| ▸ | ABL1 | P00519 | 6/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.41 |
| ▸ | SRC | P12931 | 5/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.41 |
| ▸ | PRKDC | P78527 | 5/20 | 0.41 |
| ▸ | HCK | P08631 | 4/20 | 0.41 |
| ▸ | MTOR | P42345 | 4/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19414400 | 0.91 | CYP1A1 (0.47) | EGFRABL1KDRPIK3CDSRC | |
| SCHEMBL152637 | 0.85 | PIK3CD (0.49) | EGFRABL1KDRPIK3CDSRC | |
| SCHEMBL16783676 | 0.81 | BACE1 (0.40) | EGFRABL1KDRPIK3CDSRC | |
| SCHEMBL145785 | 0.81 | SRC (0.56) | EGFRABL1KDRPIK3CDSRC | |
| SCHEMBL149528 | 0.80 | KDR (0.52) | EGFRABL1KDRPIK3CDSRC | |
| SCHEMBL19414291 | 0.77 | SRC (0.40) | EGFRABL1KDRPIK3CDSRC | |
| SCHEMBL19414290 | 0.77 | SRC (0.57) | EGFRABL1KDRPIK3CDSRC | |
| SCHEMBL11975 | 0.76 | PIK3CB (0.39) | EGFRABL1KDRPIK3CDSRC | |
| SCHEMBL18235468 | 0.76 | KDR (0.49) | EGFRABL1KDRPIK3CDSRC | |
| SCHEMBL10811 | 0.76 | SRC (0.57) | EGFRABL1KDRPIK3CDSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | claimed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-04-11 | — | — | US | disclosed |
| EP-3444242-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2019-02-20 | — | — | EP | disclosed |
| EP-2496567-B1 | NOVEL BENZOPYRAN KINASE MODULATORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-07-12 | — | — | EP | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9421209-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-23 | — | — | US | disclosed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | EGFR 929/4885ABL1 329/4885KDR 866/4885 |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | EGFR 1359/4885ABL1 334/4885KDR 1139/4885 |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | EGFR 1667/4885ABL1 465/4885KDR 1162/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | EGFR 1667/4885ABL1 465/4885KDR 1162/4885 |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKAR2B | EGFR 1502/4885ABL1 464/4885KDR 906/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | EGFR 1667/4885ABL1 465/4885KDR 1162/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | EGFR 1667/4885ABL1 465/4885KDR 1162/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | EGFR 1667/4885ABL1 465/4885KDR 1162/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | EGFR 807/4885ABL1 376/4885KDR 1038/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | EGFR 510/4885ABL1 258/4885KDR 823/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | EGFR 1667/4885ABL1 465/4885KDR 1162/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | EGFR 1667/4885ABL1 465/4885KDR 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.